Ana Szarfman

4.7k total citations · 2 hit papers
63 papers, 3.1k citations indexed

About

Ana Szarfman is a scholar working on Epidemiology, Immunology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ana Szarfman has authored 63 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Epidemiology, 15 papers in Immunology and 14 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ana Szarfman's work include Trypanosoma species research and implications (30 papers), Pharmacovigilance and Adverse Drug Reactions (10 papers) and Malaria Research and Control (8 papers). Ana Szarfman is often cited by papers focused on Trypanosoma species research and implications (30 papers), Pharmacovigilance and Adverse Drug Reactions (10 papers) and Malaria Research and Control (8 papers). Ana Szarfman collaborates with scholars based in United States, Argentina and United Kingdom. Ana Szarfman's co-authors include Stella G. Machado, Isabella A. Quakyi, David Walliker, William T. London, Richard Carter, Thomas F. McCutchan, Thomas R. Burkot, Lynn M. Corcoran, Thomas E. Wellems and Scott A. Rivkees and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

Ana Szarfman

63 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic Analysis of the Human Malaria Parasite Plasmodium falciparum

1987 594 citations David Walliker, Isabella A. Quakyi et al. Science profile →
Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports Database

2002 510 citations Ana Szarfman, Stella G. Machado et al. Drug Safety profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ana Szarfman United States	23	1.3k	935	743	593	533	63	3.1k
Juntra Karbwang Thailand	38	3.0k 2.4×	572 0.6×	194 0.3×	55 0.1×	595 1.1×	165	4.7k
L. H. Schmidt Germany	28	1000 0.8×	333 0.4×	358 0.5×	22 0.0×	1.3k 2.4×	115	4.1k
Douglas S. Walsh United States	36	1.4k 1.1×	667 0.7×	493 0.7×	24 0.0×	501 0.9×	115	3.2k
Cristina Parolin Italy	31	240 0.2×	898 1.0×	2.3k 3.1×	101 0.2×	1.8k 3.3×	104	5.8k
H. Kyle Webster Thailand	36	3.1k 2.5×	624 0.7×	838 1.1×	17 0.0×	745 1.4×	122	4.4k
Benjamin Mordmüller Germany	41	3.1k 2.5×	449 0.5×	1.3k 1.7×	26 0.0×	1.1k 2.1×	183	5.1k
T Chongsuphajaisiddhi Thailand	36	4.3k 3.4×	408 0.4×	564 0.8×	16 0.0×	488 0.9×	87	5.1k
L E Holland United States	19	227 0.2×	1.3k 1.3×	632 0.9×	44 0.1×	662 1.2×	29	5.9k
Andrea Savarino Italy	27	464 0.4×	469 0.5×	406 0.5×	32 0.1×	754 1.4×	79	3.2k
Matthias Eberl United Kingdom	43	545 0.4×	528 0.6×	3.0k 4.1×	32 0.1×	1.7k 3.2×	97	5.7k

Countries citing papers authored by Ana Szarfman

Since Specialization

Citations

This map shows the geographic impact of Ana Szarfman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Szarfman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Szarfman more than expected).

Fields of papers citing papers by Ana Szarfman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Szarfman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Szarfman. The network helps show where Ana Szarfman may publish in the future.

Co-authorship network of co-authors of Ana Szarfman

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Szarfman. A scholar is included among the top collaborators of Ana Szarfman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Szarfman. Ana Szarfman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Szarfman, Ana, Joseph M. Tonning, Frank Weichold, et al.. (2022). Recommendations for achieving interoperable and shareable medical data in the USA. SHILAP Revista de lepidopterología. 2(1). 86–86. 22 indexed citations

Harpaz, Rave, et al.. (2022). Signaling COVID-19 Vaccine Adverse Events. Drug Safety. 45(7). 765–780. 15 indexed citations

Winnenburg, Rainer, Alfred Sorbello, Rave Harpaz, et al.. (2015). Leveraging MEDLINE indexing for pharmacovigilance – Inherent limitations and mitigation strategies. Journal of Biomedical Informatics. 57. 425–435. 18 indexed citations

Harpaz, Rave, Greg Gaskin, William DuMouchel, et al.. (2014). A time-indexed reference standard of adverse drug reactions. Scientific Data. 1(1). 140043–140043. 33 indexed citations

Hausner, Elizabeth A., et al.. (2013). Qualification of cardiac troponins for nonclinical use: A regulatory perspective. Regulatory Toxicology and Pharmacology. 67(1). 108–114. 12 indexed citations

Colman, Eric, et al.. (2008). An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiology and Drug Safety. 17(11). 1068–1076. 41 indexed citations

Szarfman, Ana, Joseph M. Tonning, Jonathan G. Levine, & P. Murali Doraiswamy. (2006). Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(6). 748–758. 106 indexed citations

Almenoff, June S., Joseph M. Tonning, A. Lawrence Gould, et al.. (2005). Perspectives on the Use of Data Mining in Pharmacovigilance. Drug Safety. 28(11). 981–1007. 173 indexed citations

Szarfman, Ana, et al.. (2002). Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports Database. Drug Safety. 25(6). 381–392. 510 indexed citations breakdown →

10.

Klotz, F., et al.. (1996). Cross-Reactive Epitope among Proteins in Plasmodium falciparum Maurer's Clefts and Primate Leukocytes and Platelets. American Journal of Tropical Medicine and Hygiene. 54(6). 655–659. 5 indexed citations

11.

Szarfman, Ana, et al.. (1996). Assessment of Risk for Photocarcinogenesis: Regulatory Reviewer Viewpoint. Photochemistry and Photobiology. 63(4). 362–365. 4 indexed citations

12.

Szarfman, Ana, et al.. (1988). Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages.. The Journal of Experimental Medicine. 167(1). 231–236. 36 indexed citations

13.

Towbin, Harry, Günter Rosenfelder, Jörgen Wieslander, et al.. (1987). Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl(alpha 1-3)-galactose epitopes.. The Journal of Experimental Medicine. 166(2). 419–432. 145 indexed citations

14.

Walliker, David, Isabella A. Quakyi, Thomas E. Wellems, et al.. (1987). Genetic Analysis of the Human Malaria Parasite Plasmodium falciparum. Science. 236(4809). 1661–1666. 594 indexed citations breakdown →

15.

Szarfman, Ana, Victor P. Terranova, Stephen I. Rennard, et al.. (1982). Antibodies to laminin in Chagas' disease.. The Journal of Experimental Medicine. 155(4). 1161–1171. 148 indexed citations

16.

Szarfman, Ana, et al.. (1976). [The technic of immunoperoxidase in the detection of acute Chagas' disease].. PubMed. 36(4). 330–6. 1 indexed citations

17.

Szarfman, Ana, E L Khoury, Patricío M. Cossio, Roberto M. Arana, & Irving G. Kagan. (1975). Investigation of the Evi Antibody in Parasitic Diseases Other Than American Trypanosomiasis. American Journal of Tropical Medicine and Hygiene. 24(1). 19–24. 7 indexed citations

18.

Szarfman, Ana, et al.. (1975). Immunological studies in Rockland mice infected with T. cruzi. Development of antinuclear antibodies.. PubMed. 22(6). 489–95. 9 indexed citations

19.

Cossio, Patricío M., et al.. (1974). Chagasic Cardiopathy. Circulation. 49(1). 13–21. 167 indexed citations

20.

Schmuñis, Gabriel A., et al.. (1973). Cell mediated immunity in mice inoculated with epimastigotes or trypomastigotes of Trypanosoma cruzi.. 24(1). 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact